Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Similar articles for PubMed (Select 15620476)

1.

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC.

Vaccine. 2005 Jan 11;23(8):1029-36.

PMID:
15620476
2.

Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines.

Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, van Kampen KR, Elmets CA, Tang DC.

J Virol. 2001 Dec;75(23):11474-82.

3.

Protection of chickens against avian influenza with nonreplicating adenovirus-vectored vaccine.

Toro H, Tang DC.

Poult Sci. 2009 Apr;88(4):867-71. doi: 10.3382/ps.2008-00333.

PMID:
19276437
4.

Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR.

Expert Rev Vaccines. 2009 Apr;8(4):469-81. doi: 10.1586/erv.09.1. Review.

5.

Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines.

Zhang J.

Viruses. 2012 Nov 1;4(11):2711-35. doi: 10.3390/v4112711. Review.

6.

Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.

Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.

Vaccine. 2009 Jun 2;27(27):3561-7. doi: 10.1016/j.vaccine.2009.03.062. Epub 2009 Apr 10.

PMID:
19464535
7.

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.

Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.

Hum Vaccin. 2005 Jan-Feb;1(1):37-42. Epub 2005 Jan 12.

8.

A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.

Samdal HH, Bakke H, Oftung F, Holst J, Haugen IL, Korsvold GE, Kristoffersen AC, Krogh G, Nord K, Rappuoli R, Berstad AK, Haneberg B.

Hum Vaccin. 2005 Mar-Apr;1(2):85-90. Epub 2005 Mar 16.

9.

Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases.

Zhang J, Tarbet EB, Toro H, Tang DC.

Expert Rev Vaccines. 2011 Nov;10(11):1539-52. doi: 10.1586/erv.11.141. Review.

PMID:
22043954
10.

Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine.

Toro H, Tang DC, Suarez DL, Zhang J, Shi Z.

Vaccine. 2008 May 19;26(21):2640-6. doi: 10.1016/j.vaccine.2008.02.056. Epub 2008 Mar 17.

11.

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.

Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L.

Vaccine. 2006 Jan 16;24(3):254-62. Epub 2005 Aug 15.

PMID:
16129526
12.

Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.

Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L.

Vaccine. 2006 Mar 6;24(10):1601-8. Epub 2005 Oct 14.

PMID:
16303215
13.

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.

Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.

Vaccine. 2006 May 1;24(18):3990-4006. Epub 2005 Dec 27.

PMID:
16516356
15.

Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector.

Toro H, Tang DC, Suarez DL, Sylte MJ, Pfeiffer J, Van Kampen KR.

Vaccine. 2007 Apr 12;25(15):2886-91. Epub 2006 Sep 25.

16.

Review of intranasal influenza vaccine.

Glueck R.

Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):203-11.

PMID:
11516789
17.

Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.

Bakke H, Samdal HH, Holst J, Oftung F, Haugen IL, Kristoffersen AC, Haugan A, Janakova L, Korsvold GE, Krogh G, Andersen EA, Djupesland P, Holand T, Rappuoli R, Haneberg B.

Scand J Immunol. 2006 Mar;63(3):223-31.

PMID:
16499576
18.

Seasonal influenza vaccines.

Fiore AE, Bridges CB, Cox NJ.

Curr Top Microbiol Immunol. 2009;333:43-82. doi: 10.1007/978-3-540-92165-3_3. Review.

PMID:
19768400
19.

[Comparative clinical trial of vaccines against avian influenza].

Zverev VV, Katlinskiĭ AV, Kostinov MP, Zhirova SN, Erofeeva MK, Stukova MA, Korovkin SA, Mel'nikov SIa, Semchenko AV, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6. Russian.

PMID:
17672124
20.

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A.

J Infect Dis. 2009 Sep 15;200(6):841-8. doi: 10.1086/605505. Erratum in: J Infect Dis. 2009 Dec 1;200(11):1801-2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk